Evaluation Of Coverage and Compliance of Mass Drug Administration Programme 2011 For Elimination of Lymphatic Filariasis in Nalgonda District Of Andhra Pradesh, India

Authors

  • Abhay S Nirgude Kamineni Institute of Medical Sciences, Narketpally, Andhra Pradesh, India
  • Poonam R Naik Kamineni Institute of Medical Sciences, Narketpally, Andhra Pradesh, India
  • Nagaraj Kondagunta Kamineni Institute of Medical Sciences, Narketpally, Andhra Pradesh, India
  • Sidramappa S Reshmi Kamineni Institute of Medical Sciences, Narketpally, Andhra Pradesh, India
  • Anant A Takalkar Kamineni Institute of Medical Sciences, Narketpally, Andhra Pradesh, India
  • VG Prasad Kamineni Institute of Medical Sciences, Narketpally, Andhra Pradesh, India

Keywords:

Lymphatic Filariasis, Coverage Rate, Compliance Rate, Mass Drug Administration

Abstract

Background and Objectives: Lymphatic Filariasis has been a major public health problem in India next only to malaria. Government of India during 2004 initiated Mass DrugAdministration (MDA) with annual single dose of DEC tablets to all the population living atthe risk of Filariasis. Mass Drug Administration of Diethyl Carbamazine (DEC) &Albendazole (ALB) was undertaken in 16 districts of Andhra Pradesh on 9th, 10th and 11th December 2011. Present study aimed to evaluate coverage and compliance rate of Mass Drug Administration for lymphatic Filariasisin Nalgonda district of Andhra Pradesh.

Methods: Community Based cross-section study was undertaken among four selected clusters of Nalgonda district as per National Vector Borne Disease Control Programme (NVBDCP) guidelines. Information pertaining to coverage and compliance of MDA was gathered from 120 families from 4 clusters by interview technique using structured questionnaire.

Results: The average family size was 4.21 and majority of the respondents were males and of more than 15 years of age. The eligibility, coverage and compliance rates were 96.2%, 79.7% and 43.04% respectively. On the spot consumption of tablets was reported by only 22.9% respondents. Most common cause for non-compliance was fear of side effects (47.5%).I E C activity was reported to be seen by only 21.7% respondents.

Conclusion: Improving the community compliance in DEC consumption is the major challenge. There is an urgent need for effective MDA strategy with emphasis on Advocacy, social mobilization and monitoring.

References

National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Lymphatic Filariasis.Magnitude of disease. Website: Available from:http://nvbdcp.gov.in/fil10.html. [cited on 2012 Mar 25].

WHO: Lymphatic Filariasis fact sheet WHO Updates. Available at http://www.who.int/mediacentre/factsheets/fs102/en/ [cited on 2012 Mar 25].

National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Lymphatic Filariasis.Upscaling of mass drug administration. Website: Available from:http://nvbdcp.gov.in/filariasis-new.htmlhttp. [ cited on 2012 Mar 26].

KS Ravish, TS Ranganath, Basha S Riyaz. Coverage and compliance of Mass Drug Administration for elimination of lymphatic filariasis in endemic areas of Bijapur district, Karnataka. International Journal of Basic Medical Sciences 2011; 2:86-9.

Kumar Pradeep, Prajapati PB, Saxena Deepak, Kavishwar B Abhay, George Kurian. An evaluation of coverage and compliance of Mass Drug Administration for elimination of lymphatic filariasis in endemic areas of Gujarat. Indian Journal of Community Medicine 2008; 33: 38-42.

Karamkar P Ray, K Mitra, ChatterjeeAnirban, PK jana, Bhattacharya S, Lahiri SK. A study on coverage, compliance and awareness about Mass Drug Administration for elimination of lymphatic filariasis in a district of West Bengal, India. J Vector Borne Dis 2011;48:101-4.

Guidelines on filariasis control in India and its elimination (2009) . Available at http://nvbdcp.gov.in/Doc/Guidelines-Filariasis-Elimination-India.pdf. [cited on 2012 Mar 25].

NVBDCP Home Page: Guidelines for vector borne diseases. Lymphatic Filariasis.Guidelines for Drug Distributors in elimination of lymphatic filariasis. Available at http://nvbdcp.gov.in/Doc/drug_distrib_manual_LF.pdf [cited on 2012 Mar 25].

National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Lymphatic Filariasis. MDA Coverage since 2007. Available from:http://nvbdcp.gov.in/fil-mda.html[cited on 2012 Mar 28].

Saiprasad G S, TakalkarAnant A, Prasad V G, NirgudeAbhay S, NaikPoonam R, PalveSachin. Evaluation of Mass Drug Administration In Elimination of Lymphatic Filariasis In Nalgonda District. Narketpally: Department of Community Medicine, KIMS;2010.

ICMR. Prospects of eliminating lymphatic filariasis in India.ICMR Bulletin 2002; 32: 1-14.

TR Mani, R. rajendra, A Munirathinam, IP Sunish, S. Md Abdullah, DJ Augustin. Efficacy of co-administration of Albendazole and Diethylcarbamazine against geohelminthiases: a study from south India. Tropical Medicine and International Health 2002;7:541-8.

S Sabesan, P Vanamail, KHK Raju, P Jambulingam. Lymphatic Filariasis in India: Epidemiology and control measures. Journal of Postgraduate Medicine 2010;56:232-8.

The 6th Meeting of the Global Alliance to Eliminate Lymphatic Filariasis: A half-time review of lymphatic filariasis elimination and its integration with the control of other neglected tropical diseases. Parasites & Vectors 2010 3:100.

Downloads

Published

2012-06-30

How to Cite

1.
Nirgude AS, Naik PR, Kondagunta N, Reshmi SS, Takalkar AA, Prasad V. Evaluation Of Coverage and Compliance of Mass Drug Administration Programme 2011 For Elimination of Lymphatic Filariasis in Nalgonda District Of Andhra Pradesh, India. Natl J Community Med [Internet]. 2012 Jun. 30 [cited 2024 Jun. 18];3(02):288-93. Available from: https://njcmindia.com/index.php/file/article/view/1698

Issue

Section

Original Research Articles